Objectives:

·       Present an overview of the current and near term Digital Therapeutics landscape with a focus on current stages of development.

·       Review the impact of COVID-19 as an accelerator for the development and use of Digital Therapeutics.

·       Detail real world applications of Digital Therapeutics to illustrate the potential it holds in driving transformation of clinical practices to improve patient outcomes.

·       Examine how Medical Affairs can help act as a strategic partner and shape the trajectory of the Digital Therapeutics pipeline and life-cycle.